Chris Lowe

Chris Lowe

Editor, Inner Circle

In 2001, Chris began his career in London, England as an analyst for the international financial markets news agency Reuters.

He later became an investigative reporter in his native Ireland. He worked for The Phoenix magazine, covering the real estate boom and bust there in the mid-2000s.

In 2007, Chris decided to “go independent.” He became an analyst at The Agora, the publishing firm founded by Bill Bonner in 1979.

With Bonner & Partners publisher Will Bonner (Bill’s eldest son), Chris helped launch Agora’s first foray into the Latin American market – with a financial publishing project in Buenos Aires, Argentina.

Now, his mission is to bring readers like you the best investing and wealth-protection ideas, insights, and recommendations from the Legacy Research team.

Chris also heads up Legacy Research’s daily e-letter, The Daily Cut. It’s a daily selection of the best ideas and recommendations from the Legacy team.

Chris is happiest when he’s traveling the world, tracking down opportunities for readers. He’s currently based in Lisbon, Portugal.

Recent Articles

Coronavirus Probably Isn’t as Bad as It Seems for Stocks

By Chris Lowe, Editor, Inner Circle

No matter what happens next with the coronavirus, every prudent investor should always be prepared for the worst.

As Brexit Uncertainty Clears, It’s a Great Time to Invest in British Stocks

By Chris Lowe, Editor, Inner Circle

Although most amateur investors run away from stocks that are cheap and unloved, the pros know these are where to make the real money.

Gold Will Take a Short-Term Dip Before Its Monster Rally

By Chris Lowe, Editor, Inner Circle

If you’re still building a position in gold, now is not the time to buy. It’s worth hanging on for better prices ahead.

The Daily Cut: Don’t Let the FDA Scare You Away From CBD

By Chris Lowe, Editor, Inner Circle

Stick to cannabis companies with at least double-digit sales growth, little debt, and cash and equivalents making up 20% of the market cap.

CRISPR Has the Potential to Cure Cancer and Make You Triple-Digit Gains

By Chris Lowe, Editor, Inner Circle

CRISPR is a great addition to your stock wish list. If we get a correction, this is a solid long-term addition to your portfolio.

Load More